Fulgent Genetics Quarterly Balance Sheet
NASDAQ: FLGTHealth CareMedical SpecialitiesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Fulgent Genetics financial position
As of Jun 30, 2026, Fulgent Genetics reported total assets of $1.09 billion, down 9.2% from a year earlier against total liabilities of $93.2 million. Shareholders' equity stood at $1.00 billion, or 92.0% of assets. The company held $26.3 million in cash and equivalents against $1.5 million of debt, a net cash position of $24.8 million.
The current ratio (current assets divided by current liabilities) was 6.34, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.00.
Summary generated from market data by MetaCap's automated system. Methodology
Fulgent Genetics balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 26.30M | 23.40M | 50.19M | 117.64M | 87.88M | 67.28M | 55.14M | 58.04M | 65.11M | 54.68M | 97.47M | 84.08M |
| Short-Term Investments | 230.73M | 252.90M | 285.88M | — | — | — | 202.96M | — | — | — | — | — |
| Receivables | 64.94M | 69.28M | 84.76M | 71.19M | 77.19M | 71.48M | 69.02M | 57.31M | 56.57M | 52.06M | 51.13M | 49.28M |
| Inventory | 793.00K | 770.00K | — | — | — | — | — | — | — | — | — | — |
| Total Current Assets | 454.77M | 479.04M | 550.49M | 507.37M | 428.73M | 416.78M | 353.57M | 326.54M | 399.10M | 386.51M | 507.85M | 549.86M |
| Property, Plant & Equipment | 113.07M | 116.34M | 112.55M | 111.86M | 110.22M | 107.08M | 105.55M | 106.81M | 93.37M | 86.72M | 83.46M | 85.27M |
| Goodwill | 53.86M | 53.73M | 25.08M | 25.08M | 22.05M | 22.05M | 22.05M | 22.05M | 22.05M | 22.05M | 22.05M | 141.84M |
| Intangible Assets | 149.26M | 153.99M | 133.28M | 135.25M | 135.25M | 133.01M | 134.98M | 137.12M | 138.97M | 140.99M | 143.05M | 144.49M |
| Long-Term Investments | 294.32M | 328.29M | 369.27M | 411.78M | 484.47M | 494.11M | 570.35M | 602.23M | 526.16M | 540.50M | 423.57M | 383.66M |
| Total Assets | 1.09B | 1.16B | 1.21B | 1.21B | 1.20B | 1.21B | 1.22B | 1.23B | 1.23B | 1.23B | 1.24B | 1.36B |
| Accounts Payable | 15.55M | 21.13M | 18.65M | 18.09M | 18.89M | 18.24M | 18.36M | 19.80M | 19.87M | 19.62M | 15.36M | 15.77M |
| Total Current Liabilities | 71.76M | 90.13M | 84.97M | 72.43M | 71.33M | 65.92M | 72.90M | 73.99M | 75.75M | 75.95M | 73.02M | 61.42M |
| Long-Term Debt | 1.48M | 1.48M | 1.96M | 1.96M | 1.96M | 1.96M | 2.49M | 2.49M | 2.49M | 2.49M | 2.96M | — |
| Total Liabilities | 93.24M | 112.22M | 106.81M | 93.81M | 88.20M | 82.97M | 90.81M | 98.86M | 103.39M | 103.24M | 102.04M | 96.56M |
| Shareholders' Equity | 1.00B | 1.05B | 1.11B | 1.13B | 1.12B | 1.13B | 1.13B | 1.14B | 1.13B | 1.13B | 1.14B | 1.26B |
| Retained Earnings | 475.60M | 505.13M | 529.95M | 553.37M | 559.98M | 578.94M | 590.47M | 596.36M | 611.00M | 619.71M | 633.17M | 761.32M |
| Total Debt | 1.48M | 1.48M | 1.96M | 1.96M | 1.96M | 1.96M | 2.49M | 2.49M | 2.49M | 2.49M | 2.96M | — |
| Net Cash (Debt) | 255.56M | 274.83M | 334.12M | 115.68M | 85.92M | 65.32M | 255.61M | 55.55M | 62.62M | 52.18M | 94.51M | 84.08M |
| Shares Outstanding | 27.52M | 28.85M | 31.08M | 30.85M | 30.61M | 30.62M | 30.84M | 30.54M | 30.26M | 29.89M | 29.65M | 30.04M |
This table shows 12 quarterly periods of Fulgent Genetics's balance sheet, from Q2 2026 back to Q3 2023, across 19 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow FLGT's reporting calendar. What is a balance sheet?